Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Delayed Quote USD

Arrowhead Pharmaceuticals, Inc. (ARWR)

Compare
12.20
-0.53
(-4.20%)
At close: April 1 at 4:00:00 PM EDT
12.99
+0.78
+(6.43%)
Pre-Market: 4:20:20 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
2,500
3,551
240,735
243,231
138,287
Operating Expense
628,447
604,631
445,737
421,738
287,323
Operating Income
-625,947
-601,080
-205,002
-178,507
-149,036
Net Non Operating Interest Income Expense
-21,111
-9,632
-3,027
5,033
6,120
Other Income Expense
-1,828
-1,748
1,538
765
2,070
Pretax Income
-648,886
-612,460
-206,491
-172,709
-140,846
Tax Provision
649
-2,767
2,784
3,785
2
Net Income Common Stockholders
-639,714
-599,493
-205,275
-176,063
-140,848
Diluted NI Available to Com Stockholders
-639,714
-599,493
-205,275
-176,063
-140,848
Basic EPS
-5.15
-5.00
-1.91
-1.63
-1.36
Diluted EPS
-5.15
-5.00
-1.92
-1.67
-1.36
Basic Average Shares
124,142.25
119,784
107,312
105,960
103,745
Diluted Average Shares
124,142.25
119,784
107,312
105,960
103,745
Total Operating Income as Reported
-625,947
-601,080
-205,002
-178,507
-149,036
Total Expenses
628,447
604,631
445,737
421,738
287,323
Net Income from Continuing & Discontinued Operation
-639,714
-599,493
-205,275
-176,063
-140,848
Normalized Income
-639,714
-599,493
-205,275
-176,063
-140,848
Interest Income
27,520
22,720
15,299
5,033
6,120
Interest Expense
48,631
32,352
18,326
--
--
Net Interest Income
-21,111
-9,632
-3,027
5,033
6,120
EBIT
-600,255
-580,108
-188,165
-172,709
-140,846
EBITDA
-580,688
-561,513
-175,672
-162,288
-132,579
Reconciled Depreciation
19,567
18,595
12,493
10,421
8,267
Net Income from Continuing Operation Net Minority Interest
-639,714
-599,493
-205,275
-176,063
-140,848
Normalized EBITDA
-580,688
-561,513
-175,672
-162,288
-132,579
Tax Rate for Calcs
0
0
0
0
0
9/30/2021 - 12/16/1993

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALNY Alnylam Pharmaceuticals, Inc.
255.76
-5.28%
 
WVE Wave Life Sciences Ltd.
7.74
-4.21%
 
PRQR ProQR Therapeutics N.V.
1.2900
-3.01%
 
IONS Ionis Pharmaceuticals, Inc.
27.26
-9.65%
 
SRPT Sarepta Therapeutics, Inc.
61.91
-2.99%
 
BEAM Beam Therapeutics Inc.
17.64
-9.70%
 
RCKT Rocket Pharmaceuticals, Inc.
5.81
-12.89%
 
SGMO Sangamo Therapeutics, Inc.
0.5701
-13.07%
 
CYTK Cytokinetics, Incorporated
37.50
-6.69%
 
ABUS Arbutus Biopharma Corporation
3.4800
-0.29%